Form 4: Suzanne Nora Johnson Reports Acquisition of Phantom Stock Units in Pfizer Inc.

Director Suzanne Nora Johnson reports the acquisition of phantom stock units in Pfizer Inc. as part of deferred compensation.

Summary

• Suzanne Nora Johnson, a director of Pfizer Inc., filed a Form 4 to report changes in beneficial ownership.
• On April 25, 2024, Johnson acquired 8,115.598 phantom stock units of Pfizer common stock.
• These units were granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• The price of each phantom stock unit is $25.26.
• Following the transaction, Johnson directly owns 100,296.988 derivative securities.
• The phantom stock units represent deferred director's compensation that will be settled in cash or common stock upon Johnson's retirement from the Board of Directors.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating standard compensation practices. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of Pfizer.
• The deferred compensation plan is a common practice for non-employee directors.

Future Outlook

The document does not contain specific forward-looking statements regarding Pfizer's future performance.

Industry Context

Reporting of beneficial ownership changes by company insiders is a standard regulatory requirement to ensure transparency and prevent insider trading.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It reflects the company's compensation strategy for non-employee directors.

Key Dates